Paul M. Ridker

Cardiology
75 Francis St
Boston, MA 02115

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 642 publications

When the exposure causes selection bias: understanding why risk factors attenuate in secondary as compared with primary prevention and what to do about it.

When the exposure causes selection bias: understanding why risk factors attenuate in secondary as compared with primary prevention and what to do about it.

Journal: European heart journal
Published: September 06, 2026

Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.

Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.

Journal: Circulation
Published: August 18, 2026

Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes.

Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes.

Journal: Nature reviews. Nephrology
Published: August 06, 2026

Inflammation and the Long-Term Incidence of Hypertension in Women.

Inflammation and the Long-Term Incidence of Hypertension in Women.

Journal: European journal of preventive cardiology
Published: June 11, 2026

Targeting Inflammation in Atherosclerotic Cardiovascular Disease: Mechanisms and Emerging Therapies.

Targeting Inflammation in Atherosclerotic Cardiovascular Disease: Mechanisms and Emerging Therapies.

Journal: Immunological reviews
Published: June 05, 2026

Comparable 4-Year Stability for High-Sensitivity C-Reactive Protein and LDL Cholesterol.

Comparable 4-Year Stability for High-Sensitivity C-Reactive Protein and LDL Cholesterol.

Journal: Journal of the American College of Cardiology
Published: May 07, 2026

Genetic Risk of Cardiovascular Disease Among People With No Standard Modifiable Risk Factors.

Genetic Risk of Cardiovascular Disease Among People With No Standard Modifiable Risk Factors.

Journal: JACC. Advances
Published: April 14, 2026

Discovery of gene-alcohol interaction loci influencing blood pressure in 1.1 million individuals from multiple populations.

Discovery of gene-alcohol interaction loci influencing blood pressure in 1.1 million individuals from multiple populations.

Journal: Research square
Published: April 10, 2026

Anti-Inflammatory Effects of Oral NLRP3 Inhibition With Ruvonoflast Among Individuals at Elevated Cardiovascular Risk.

Anti-Inflammatory Effects of Oral NLRP3 Inhibition With Ruvonoflast Among Individuals at Elevated Cardiovascular Risk.

Journal: Journal of the American College of Cardiology
Published: April 10, 2026

Discovery of gene-alcohol interaction loci influencing blood pressure in 1.1 million individuals from multiple populations.

Discovery of gene-alcohol interaction loci influencing blood pressure in 1.1 million individuals from multiple populations.

Journal: Research square
Published: April 10, 2026

Interleukin-6 as a Biomarker and Treatment Target for Atherosclerotic Disease.

Interleukin-6 as a Biomarker and Treatment Target for Atherosclerotic Disease.

Journal: Journal of the American College of Cardiology
Published: April 07, 2026

A quantitative method to estimate free interleukin-6 among patients treated with the interleukin-6 ligand inhibitor ziltivekimab: comparison to C-reactive protein with implications for the ZEUS, HERMES, and ARTEMIS cardiovascular outcomes trials.

A quantitative method to estimate free interleukin-6 among patients treated with the interleukin-6 ligand inhibitor ziltivekimab: comparison to C-reactive protein with implications for the ZEUS, HERMES, and ARTEMIS cardiovascular outcomes trials.

Journal: Atherosclerosis
Published: March 31, 2026
Showing 1-12 of 642

Last Updated: 09/26/2026